David Vensel

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry · 2016 · 105 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +18

Discovery and Optimization of a Series of 3-(3-Phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Mark A. Ashwell, Jean‐Marc Lapierre, Christopher J. Brassard et al. · Journal of Medicinal Chemistry · 2012 · 98 citations · Full text

Chemical Biology, Pharmaceutical Chemistry, Biophysical Screening Strategy +19

The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands

Manish Tandon, Mary‐Margaret O'Donnell, Alex Porte et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 31 citations · Full text

Biochemistry, Medicine, Rational Drug Design +3

Calix[4]arene, calix[4]resorcarene, and cyclodextrin derivatives and their lanthanide complexes as chiral NMR shift reagents

Kristin J. Smith, James D. Wilcox, Gudrun Mirick et al. · Chirality · 2003 · 28 citations · Full text

Chiral Primary, Chiral Nmr, Biochemistry +14